Flibanserin for Treating Hypoactive Sexual Desire Disorder.

Author: Jae Hong SANG ¹ ; Tae Hee KIM ; Soo Ah KIM
Author Information

1. Department of Obstetrics and Gynecology, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Korea.
Publication Type:Review
Keywords: Flibanserin; Sexual behavior; Sexual dysfunctions, psychological; Sildenafil citrate
MeSH: Brain; Citric Acid; Female; Hand; Humans; Korea; Male; Sexual Behavior; Sexual Dysfunctions, Psychological*; United States Food and Drug Administration; Sildenafil Citrate; Tadalafil
From:Journal of Menopausal Medicine 2016;22(1):9-13
CountryRepublic of Korea
Language:English
Abstract: There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to be released in South Korea soon. Authors wrote this article to acknowledge flibanserin to sexologists for females or physicians for menopausal medicine, so that this agent can be safely used for females who have HSDD.